uniQure announced the closing of its previously announced upsized underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share.
The offering included 741,758 ordinary shares issued after the underwriters exercised their option in full to purchase additional shares.
The aggregate gross proceeds to uniQure were approximately $259 million before deducting underwriting discounts, commissions, and offering expenses. All securities in the offering were sold by uniQure.
uniQure plans to use the net proceeds to fund commercialization readiness activities, potential commercial launches of AMT-130 and related commercialization activities, and a confirmatory study for AMT-130.
The company also plans to use proceeds to support the development of other clinical product candidates, business development initiatives, research projects, and general corporate purposes.
Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets acted as joint bookrunning managers for the offering. H.C. Wainwright & Co. acted as lead manager.
uniQure is a gene therapy company focused on developing single-treatment therapies with potentially curative results for patients with severe medical needs.
The company is advancing a pipeline of proprietary gene therapies targeting Huntington’s disease, refractory temporal lobe epilepsy, Fabry disease, and other severe diseases.
uniQure’s work builds on its history in gene therapy, including its approved gene therapy for hemophilia B, which represented a major milestone in genomic medicine.
